Maryland Team Wins First Phase of NEI Contest to Create Human Retina

October 6, 2017: By Jon Swedien
Erin Lavik, ScD

Erin Lavik, ScD

A team from the University of Maryland, Baltimore County, beat out 12 other entries to win the first phase of a National Eye Institute (NEI) contest to create a living model of the human retina.

The NEI, part of the National Institutes of Health, announced the winner Sept. 28. The honor included a prize of $90 thousand.

The NEI’s 3-D Retina Organoid Challenge (3-D ROC) initiative seeks to design human retinas from stem cells. The submissions were evaluated based on their innovativeness and feasibility, the NEI said.

The winning concept was a proposal to build a retina by screen printing adult neural progenitor-derived retinal neurons in layers that mimic the structure of the human retina. The system is designed to be scalable, efficient, and reproducible, enabling high-throughput screening for drug testing, the NEI said. Erin Lavik, ScD, led the winning team.

The NEI plans to launch a second phase of the contest this fall and to award a combined total of $1 million to teams that demonstrate the functionality of a retina organoid prototype. Further details on the challenge will be provided in an official announcement, NEI said.

NEI also awarded five teams with an honorable mention. They were led by:

–Rebecca Carrier, PhD, Northeastern University, Boston;

–David Gamm, MD, PhD, University of Wisconsin, Madison;

–Wei Liu, PhD, Albert Einstein College of Medicine, Bronx, New York;

–Daniel Pelaez, PhD, University of Miami, Florida;

–Katja Schenke-Layland, PhD, Fraunhofer Institute for Interfacial Engineering and Biotechnology, Stuttgart, Germany.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Optical Coherence Tomography Report: A Global Market Analysis for 2017 to 2023